Evidence map›Paper›PMID 32153734›Full record

ArticleAvicenna journal of medical biotechnology

Optimization of

Farzaneh Peighambarzadeh, Anahita Najafalizadeh, Nafiseh Esmaeil, Abbas Rezaei, Farzaneh Ashrafi, Mazdak Ganjalikhani Hakemi

Open access · greenAbstract read
In one paragraph

Article in Avicenna journal of medical biotechnology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Temporal Expression of Transcription FactorACS synthetic biology · 2022
    Article
  4. Advances in NK cell production.Cellular & molecular immunology · 2022
    Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Farzaneh PeighambarzadehDepartment of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Anahita NajafalizadehDepartment of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Nafiseh EsmaeilDepartment of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Abbas RezaeiDepartment of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Farzaneh AshrafiHematology Division, Department of Internal Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Mazdak Ganjalikhani HakemiDepartment of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Isfahan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRegarding to the increase of cancer deaths in recent years and disability of common therapies to eradicate cancers, as well as expansion of Natural Killer (NK) cell therapy, it seems so vital to find new useful therapies against cancers. Breast cancer is the second main cause of cancer death among women. As it is impossible for a majority of patients to receive NK cell therapy, an attempt was made to establish a low-cost and efficient method for expanding and activating NK cells against breast cancer cell line (MCF7).

methodsNK cells were isolated from Peripheral Blood Mononuclear Cells (PBMCs) applying either MACS based NK cell enrichment kit or antibodies and complement as cytotoxic method. Then, the NK cells were cultured in Stem Cell Growth Medium (SCGM) with feeder layer (irradiated PBMCs) along with PHA or OKT3. IL-2, IL-15 and IL-21 were used to expand NK cells and finally their cytotoxic activity was investigated by flow cytometry.

resultsHighly pure NK cells were obtained and no significant difference between the two isolation methods was found. Using IL-2 plus IL-15, the number of NK cells increased up to100 fold after 16 days. No significant effect was observed after IL-21 treatment.

conclusionOur data indicated that cytotoxicity method can be considered a low-cost alternative for NK cell isolation kits. It seems that culturing NK cells for 14 days in either PHA or OKT3 supplemented SCGM medium would be more effective than culturing for 16 days in the presence of IL-21.

Indexed as

ImmunotherapyInterleukins (IL)Natural killer cells

Identifiers

PMID32153734
PMCPMC7035457
OpenAlexW3013212211

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.